# Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

> **NCT03910439** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 4 (actual)

## Conditions studied

- Myeloma, Multiple
- Myeloma-Multiple

## Interventions

- **BIOLOGICAL:** Avelumab
- **RADIATION:** External beam radiotherapy

## Key facts

- **NCT ID:** NCT03910439
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-17
- **Primary completion:** 2020-11-04
- **Final completion:** 2020-11-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow/Insufficient accrual/COVID-19 pandemic
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03910439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03910439, "Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT03910439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*